[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemophagocytic-lymphohistiocytoses\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemophagocytic-lymphohistiocytoses":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,68,89,109,150,191,217,242,265,290],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100294752","prospective-cohort-for-adult-hemophagocytosis-100294752",false,"NCT03117010","Prospective Cohort for Adult Hemophagocytosis","A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like Syndrome","Inclusion Criteria:\n\n* Subjects should fulfill the following criteria\n\n  1. Subjects should have at least one of the following problems\n\n     1. Presence of hemophagocytosis in tissue or bone marrow\n     2. Presence of at least 3 conditions among 8 conditions of HLH diagnostic criteria\n  2. Age \\> 18 years\n  3. Written informed consents\n\n     Exclusion Criteria:\n* Subjects cannot satisfy the inclusion criteria","ALL","18 Years","80 Years",{"count":20,"type":21},81,"ESTIMATED","3 Years","OBSERVATIONAL","This prospective study enrolls subjects who have clinical and laboratory manifestations related with hemophagocytic lymphohistiocytosis. The purpose of the study is to evaluate clinical and biological features of adult hemophagocytic lymphohistiocytosis. The enrolled subjects into this study will be evaluated according to the HLH (hemophagocytic lymphohistiocytosis)criteria and treated with systemic immunosuppressive therapy or chemotherapy. All subjects will be regularly monitored by physicians participating in this study.",[26],"Hemophagocytic Lymphohistiocytoses",[28],"Hemophagocytic lymphohistiocytosis","RECRUITING","2026-04-23",{"date":32,"type":33},"2026-04-24","ACTUAL",{"date":35,"type":33},"2017-01-01",{"date":37,"type":21},"2028-12-31",{"name":39,"class":40},"Samsung Medical Center","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100528439","phase-2-ruxolitinib-with-de-intensified-hlh-94-for-the-treatment-of-hemophagocytic-lymphohistiocytosis-hlh-100528439","NCT06160791","Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)","Frontline Ruxolitinib With De-Intensified HLH-94 for Adult Hemophagocytic Lymphohistiocytosis (HLH): A Multicenter, Single-Arm Phase 2 Study","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign a written informed consent document.\n* Males and females, 18 years of age or older at the time of enrollment.\n* Participants must have active HLH and meet \\>= 5 of 8 of the HLH-2004 diagnostic criteria, or have familial\u002Fprimary HLH with pathogenic\u002Flikely pathogenic germline variant(s) in genes known to cause HLH (e.g., PRF1, UNC13D, Syntaxin 11 (STX11), Syntaxin-binding protein 2 (STXBP2), RAB27A, SH2 domain-containing protein 1A (SH2D1A), baculovirus inhibitor of apoptosis repeat containing protein 4 (BIRC4), Lysosomal trafficking regulator (LYST), interleukin-2-inducible T-cell kinase (ITK), SLC7A7, X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia (XMEN), Hermansky-Pudlak syndrome (HPS), NLR family CARD domain-containing protein 4 (NLCR4) or other immune regulatory genes.\n\n  * Fever \\>= 38.5 degrees Celsius (C) (or \\>= 38 degrees C if acetaminophen given in prior 6 hours).\n  * Splenomegaly.\n  * Peripheral cytopenias involving \\>= 2 of 3 cell lines (absolute neutrophil count \\\u003C 1000\u002FuL; hemoglobin \\\u003C 9 g\u002FdL; platelets \\\u003C 100,000\u002FuL).\n  * Hypertriglyceridemia (fasting triglycerides \\>= 265 mg\u002FdL) or Hypofibrinogenemia (fibrinogen =\\\u003C 150 g\u002FdL).\n  * Hemophagocytosis on tissue biopsy, such as in the bone marrow, spleen, lymph node, or liver.\n  * Low\u002Fabsent natural killer (NK)-cell activity\u002Fperforin and\u002For decreased CD107a mobilization.\n  * Ferritin \\>= 500 ug\u002FL.\n  * Soluble IL-2 receptor (sCD25) \\> 2400 U\u002FmL or two standard deviations above age-adjusted laboratory-specific norms.\n* The effects of ruxolitinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception for the duration of study participation and for two months after last administration of study treatment.\n\n  * Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n  * Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and two months after last administration of study treatment.\n\nExclusion Criteria:\n\n* Participant is receiving or received any other investigational agent within 1 week of the first dose of treatment.\n* Females who are pregnant or breastfeeding. Female participants of child-bearing potential must have a negative pregnancy test within 7 days of treatment and lactating females must discontinue breast feeding during treatment and until two weeks after the final dose of ruxolitinib.\n* Males who expect to conceive children, and\u002For who decline highly effective methods of contraception during the entire duration of the study.\n* Patient cannot take medications orally or via a nasogastric\u002Forogastric tube.\n* Poor life expectancy \\\u003C 2 weeks.\n* Clinically significant or uncontrolled cardiovascular disease, including unstable angina, acute myocardial infarction, or stroke within 6 months, New York Heart Association class III or IV. congestive heart failure, and arrhythmia requiring therapy or uncontrolled hypertension (blood pressure \\> 170\u002F100 mmHg) unless approved by the sponsor- investigator.\n* Estimated creatine clearance (CrCl) \\\u003C 15 mL\u002Fmin while not on dialysis.\n* Known (biopsy-confirmed) liver cirrhosis or suspected cirrhosis with a Model for End- Stage Liver Disease (MELD) score of \\> 20, or aspartate aminotransferase (AST) or alanine transaminase (ALT) values \\> 1000 not expected to improve with HLH therapy.\n* Severe organ dysfunction, such as cardiorespiratory failure requiring inotropic medications or extracorporeal life support. Respiratory support including intubation\u002Fventilation is allowed.\n\n  \\* Vasopressors are allowed if not required other than low dose vasoconstrictors to compensate the effects of sedation.\n* Newly diagnosed acute and clinically active tuberculosis, hepatitis B, and\u002For hepatitis C.\n\n  * Patients with active human immunodeficiency virus (HIV) are not excluded from this study but must be on antiretrovirals.\n  * Patients with hepatitis B or C viremia can be on study if the hepatitis is not considered clinically active and\u002For if it is chronic. These patients should be discussed with the principal investigator.\n* Individuals with a prior malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Individuals with chimeric antigen receptor (CAR)-T-associated HLH.\n* No prior HLH-directed therapy except corticosteroids for \\\u003C 2 consecutive weeks and anakinra.\n\n  * Adjunctive approaches such as rituximab for Epstein-Barr virus (EBV) viremia or IVIG for viral infection are permitted.\n  * Emapalumab, alemtuzumab, anti-thymocyte globulin (ATG), tocilizumab, siltuximab, or prior ruxolitinib are NOT permitted. Cyclosporine and tacrolimus are not permitted in the initial induction period.\n* Hypersensitivity to ruxolitinib or any of its excipients",{"count":50,"type":21},36,"INTERVENTIONAL",[53],"PHASE2","This phase II trial tests the effects of ruxolitinib in combination with a de-intensified HLH-94 drug regimen has on patients with newly diagnosed hemophagocytic lymphohistiocytosis (HLH), a disorder caused by dysregulated immune responses (that is, immune responses that are too strong and cause inflammatory damage to normal tissues). The therapy used for HLH decreases the activity of the immune system. Ruxolitinib is a type of drug called a kinase inhibitor. It works by blocking the signals that cause inflammatory cells to multiply. De-intensified HLH-94 is a treatment regimen that includes 4 weeks of dexamethasone with the dose being decreased each week, and up to 4 weeks of etoposide. This combination is commonly used to treat HLH. Dexamethasone is a steroid medication that works by fighting inflammation. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill cancer cells and is used to kill the types of white blood cells in HLH that are attacking the body. Giving ruxolitinib in combination with a de-intensified HLH-94 drug regimen may reduce toxic exposure to therapy while maintaining efficacy in patients with HLH.",[26],[57],"HLH-94","2026-04-07",{"date":60,"type":33},"2026-04-13",{"date":62,"type":33},"2024-10-01",{"date":64,"type":21},"2029-11-30",{"name":66,"class":40},"Jerry Lee, MD, MSc, MPhil",3,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":77,"studyType":23,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":41},"100460564","into-hlh-a-disease-registry-for-patients-with-hemophagocytic-lymphohistiocytosis-hlh-100460564","NCT05277272","INTO-HLH: A Disease Registry for Patients With Hemophagocytic Lymphohistiocytosis (HLH)","INTO-HLH- Insight Into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): A Disease Registry for Patients With HLH","Inclusion Criteria:\n\n* Patients with clinically suspected or confirmed HLH, including those meeting the HLH-2004 diagnostic criteria (primary or secondary forms, including malignancy) and other forms of HLH (macrophage activation syndrome \\[MAS\\], cytokine release syndrome \\[CRS\\], etc.)\n* Signed and dated informed consent and assent (adolescents)\n\nExclusion Criteria:\n\n* None",{"count":76,"type":21},200,"5 Years","The purpose of this observational study is to collect data on the natural history of disease of patients with Hemophagocytic Lymphohistiocytosis (HLH) including diagnosis, treatments, responses, and outcomes.",[26],"2026-02-23",{"date":82,"type":33},"2026-02-24",{"date":84,"type":33},"2021-12-31",{"date":86,"type":21},"2027-01",{"name":88,"class":40},"Children's Hospital Medical Center, Cincinnati",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":41},"100508289","describing-treatment-outcomes-and-responses-in-lymphoma-associated-hemophagocytic-lymphohistiocytosis-100508289","NCT05898477","Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n* Patients with lymphoma that are fulfilling at least one of the following:\n\nA. Meeting 5 of 8 HLH-2004 diagnostic criteria OR B. Are OHI index positive (sCD25\\>3,900 U\u002FmL and ferritin\\>1,000 ng\u002FmL)\n\nExclusion Criteria:\n\n* Patients developing HLH\\> 1 month after lymphoma diagnosis (for aggressive lymphomas)\n* Patients with incomplete treatment and response documentation",{"count":96,"type":21},2000,"The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to improve overall survival of the patients with lymphoma associated hemophagocytic lymphohistiocytosis.",[99,26],"Lymphoma","2026-01-20",{"date":102,"type":33},"2026-01-22",{"date":104,"type":33},"2023-05-01",{"date":106,"type":21},"2028-07",{"name":108,"class":40},"University of Alabama at Birmingham",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":117,"targetDuration":119,"studyType":23,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":149},"100450503","cytosorb-treatment-of-critically-ill-patients-registry-100450503","NCT05146336","CytOSorb TreatMent Of Critically Ill PatientS Registry","CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting","COSMOS","Inclusion Criteria:\n\n1. Planned OR actual CytoSorb® 300 mL device utilization\n2. Informed consent for prospective registry participation\n\nExclusion Criteria:\n\n1. Use of the CytoSorb® 300 mL device for antithrombotic removal only\n2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only\n3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.",{"count":118,"type":21},3000,"3 Months","Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care",[122,123,124,125,126,127,128,129,130,131,132,133,26,134,135,136,137,138],"Septic Shock","Acute Respiratory Distress Syndrome","Trauma","Rhabdomyolysis","Cardiogenic Shock","Pancreatitis","Acute on Chronic Liver Failure","Acute Liver Failure","Burns","Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)","Extracorporeal Life Support","Postoperative Endocarditis","Liver Transplant; Complications","Infectious Disease","Postoperative Vasoplegic Syndrome","Drug Overdose","Sepsis","2025-09-10",{"date":141,"type":33},"2025-09-11",{"date":143,"type":33},"2022-06-22",{"date":145,"type":21},"2032-09",{"name":147,"class":148},"CytoSorbents, Inc","INDUSTRY",28,{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":17,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":41},"100431799","conception-of-a-diagnosis-prognosis-and-therapeutic-decision-tool-for-patients-with-autoimmunity-and-inflammation-100431799","NCT04902807","Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation","ATRACTion","Inclusion Criteria for controls (patients relatives and unrelated subjects):\n\n* Individuals aged\\\u003C18 y\u002Fo.\n* Individuals \\> 6 kg\n* Individuals not affected by an immune-related disease or not affected by cancer\n* Individuals whose parents have signed an enlightened consent.\n\nInclusion criteria for patients\n\n* Individuals with health insurance.\n* Patients treated at Necker hospital with PIDs and autoimmunity\u002Finflammation related to known genetic defects (cytopenia, Enteropathy Inflammatory bowel disease (IBD), Systemic Lupus Erythematosus (SLE), Juvenile Idiopathic Arthritis (JIA), Familial Hemophagocytic Lymphohistiocytosis (FHL), chronic EBV infection associated (Ca-EBV) with EBV-infected T and\u002For Natural Killer (NK) cells and with a high risk to develop macrophage activation syndrome similar to FHL. See table below for diagnosis inclusion criteria.\n* Individuals aged\\\u003C18 y\u002Fo.\n* Individuals \\> 9 kg\n* Patients whose parents have signed an enlightened consent.\n\nExclusion Criteria:\n\n* Intake of antibiotics within 2 weeks prior inclusion\n* Absence of parent's or child consent form\n* Cytotoxic cancer treatments\n* antiviral treatments (HIV, hepatitis …)\n* Short term life-threatening conditions\n* Individuals placed under judicial protection","1 Year",{"count":159,"type":21},500,"The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity\u002Finflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).",[162,163,164,165,166,167,168,169,170,171,26,172,173,174,175,176,177,178,179,180],"Autoimmune Lymphoproliferative Syndrome","Autoimmune Cytopenia","Autoimmune Diseases","Autoimmune Anemia","Autoimmune Thrombocytopenia","Autoimmune Hepatitis","Autoimmune Diabetes","Autoimmune Rheumatologic Disease","Systemic Lupus Erythematosus","Juvenile Idiopathic Arthritis","EBV Lymphoproliferation","RAS-Associated Autoimmune Leucoproliferative Disease","Primary Immunodeficiency","APECED","IPEX","BENTA","Enteropathy, Autoimmune","Combined Immunodeficiency","IBD","2025-09-02",{"date":183,"type":33},"2025-09-08",{"date":185,"type":33},"2021-09-07",{"date":187,"type":21},"2026-06",{"name":189,"class":190},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":199,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":216},"100507037","prospective-validation-of-the-ohi-index-100507037","NCT05882175","Prospective Validation of the OHI Index","A Prospective Study to Validate the Prognostic Power of the Optimized HLH Inflammatory (OHI) Index","HLH","Inclusion Criteria:\n\n* Patients with hematologic malignancies\n* At least 18 years old\n\nExclusion Criteria:\n\n* Prior recent treatment (chemotherapy\u002F other cytoreductive therapies in the last month)",true,{"count":201,"type":21},300,"Hemophagocytic lymphohistiocytosis (HLH) associated with hematologic malignancies (HM-HLH) is a syndrome with an abysmal prognosis (10-30% 5 years overall survival). The investigators have recently established an improved diagnostic and prognostic index for HM-HLH, termed the Optimized HLH Inflammatory (OHI) index. The OHI index is comprised of the combined elevation of soluble CD25 (sCD25) \\> 3,900 U\u002FmL and ferritin \\>1,000 ng\u002FmL . However, the true incidence and outcomes of HLH\u002FOHI+ in an unselected cohort are unknown, and so is the mechanism of HM-HLH.",[197,26,204,205,206],"Hemophagocytic Syndrome","Hematologic Malignancy","Hematologic Neoplasms","2025-05-08",{"date":209,"type":33},"2025-05-13",{"date":211,"type":33},"2021-03-03",{"date":213,"type":21},"2030-03-03",{"name":215,"class":40},"Meir Medical Center",2,{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":223,"eligibilityCriteria":224,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":41},"100561051","flow-cytometry-for-the-study-of-t-cell-populations-in-hemophagocytic-lymphohistiocytosis-associated-with-lymphomas-100561051","NCT06585124","Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas","Observational Study on the Application of Flow Cytometry for the Study of T-Cell Populations in Lymphoma-associated Hemophagocytic Lymphohistiocytosis","LA-HLH","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Diagnosis at onset of aggressive lymphoma including the following histotypes:\n\n   * Hodgkin lymphoma\n   * Transformed B cell lymphomas;\n   * Diffuse large B-cell lymphomas (diffuse large B-cell lymphoma NOS; T-cell\u002Fhistiocyte-rich B-cell lymphoma; High grade B-cell lymphoma\u002Fhigh grade B-cell lymphoma with MYC and BCL2 rearrangement ALK-positive large B-cell lymphoma; Large B-cell lymphoma with IRF4 rearrangement; High grade B-cell lymphoma with 11q alterations; Lymphomatoid granulomatosis; EBV-positive large B-cell lymphoma Large B-cell lymphoma associated with chronic inflammation; Fibrin-associated large B-cell lymphoma; Fluid overload-associated large B-cell lymphoma; Plasmoblastic lymphoma; Immune-privileged site B-cell lymphoma Primary cutaneous leg-type large B-cell lymphoma; Intravascular large B-cell lymphoma; Primary mediastinal large B-cell lymphoma; Mediastinal grey zone lymphoma; High grade NOS B-cell lymphoma)\n   * Burkitt lymphoma\n   * KSHV\u002FHHV8 a ssociatedlymphomas\n   * Lymphomas associated with immunodeficiency or immune dysregulation\n   * Mature T-cell-derived lymphomas (NOS peripheral T-cell lymphoma; Nodal follicular helper T-cell lymphoma; Anaplastic large cell lymphoma; Nodal and extranodal EBV-positive T\u002FNK-cell lymphomas; Hepatosplenic T-cell lymphoma; Enteropathy-associated intestinal T-cell lymphoma, epitheliotropic monomorphic and NOS; Subcutaneous T-cell lymphoma similar to panniculitis)\n3. Informed consent to the use of biologic materials for studies related to the present proposal.\n\nExclusion Criteria:\n\n1. Diagnosis of indolent non-Hodgkin's lymphoma or diagnoses other than those listed in the inclusion criteria\n2. Prolonged steroid therapy, defined as lasting more than 15 days or high doses of steroid, exceeding 1 mg\u002Fkg\n3. Age ≤ 18 years;",{"count":226,"type":21},150,"The goal of this study is to explore the associations between T cell activation and the occurrence of hemophagocytic lymphohistiocytosis (HLH) in patients with newly diagnosed lymphomas. The specific aims are:\n\nPrediction of Lymphoma-Associated HLH (LA-HLH): Compare flow cytometric T cell activation markers with the H-score to predict LA-HLH.\n\nIdentification of new markers for predicting HLH in patients with aggressive lymphoma.\n\nDescription of the incidence rate of LA-HLH. Assessment of the outcomes of LA-HLH identified by flow cytometric analysis or the H-score.\n\nThis prospective, single-center observational study will include 150 patients newly diagnosed with aggressive lymphoma within one year. Peripheral blood samples will be taken at diagnosis alongside routine blood chemistry tests for flow cytometric analysis of the T-lymphocyte activation profile. Data on disease characteristics will be collected to calculate the H-score, HLH-2004 score, and OHI score for diagnosing HLH. The flow cytometry results will be compared with these scores to evaluate their effectiveness in diagnosing LA-HLH.",[99,26],[230,231,232,197],"Flow Cytometry","T cell activation","lymphoma","2024-09-03",{"date":235,"type":33},"2024-09-05",{"date":237,"type":33},"2024-05-01",{"date":239,"type":21},"2026-05-01",{"name":241,"class":40},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":157,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":51,"phases":252,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100554818","phase-4-modified-dep-regimens-for-the-treatment-of-hemophagocytic-lymphohistiocytosis-100554818","NCT06504030","Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis","A Single-arm, Single-center, Prospective Study of Modified DEP Regimens (Doxorubicin+ Etoposide + Methylprednisolone) for the Treatment of Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n1. According to the HLH-2004 criteria, the patient meets the HLH diagnosis.\n2. 1 year old \\\u003C age \\\u003C 70 years old, regardless of gender.\n3. Before the start of the study, total bilirubin ≤ 10 times the upper limit of normal; serum creatinine ≤ 1.5 times the normal value; fibrinogen can be corrected to ≥ 0.6g\u002FL after infusion.\n\n3\\. Serum HIV antibody negative; HCV antibody negative, or HCV antibody positive, but HCV-RNA negative. HBV surface antigen and HBV core antibody are both negative. If any of the above is positive, peripheral blood hepatitis B virus DNA titer detection is required, and it must be less than 1×103 copies\u002Fml before enrollment.\n\n4\\. Women of childbearing age must be confirmed to be non-pregnant through pregnancy tests, and are willing to take effective contraceptive measures during the trial and within ≥ 6 months after the last dose; pregnant and lactating women cannot participate; all male subjects take contraceptive measures during the trial and within ≥ 3 months after the last dose.\n\n5\\. Sign the informed consent form.\n\nExclusion Criteria:\n\n1. Allergic to liposome doxorubicin, etoposide, and ruxolitinib or with severe allergic constitution;\n2. Severe myocardial damage, with myocardial enzyme CK and CK-MB increased more than 3 times ULN (upper limit of normal value).\n3. Patients with heart disease of grade II or above (including grade II) according to the New York Heart Association (NYHA) score.\n4. Subjects who have used a total cumulative dose of doxorubicin ≥300mg\u002Fm2 or a total cumulative dose of epirubicin ≥450mg\u002Fm2, or who have previously used anthracyclines to cause heart disease.\n5. Subjects with severe mental illness;\n6. Severe and uncontrollable infections, such as lung infection, intestinal infection, and sepsis.\n7. Active massive bleeding in visceral organs (including gastrointestinal bleeding, alveolar bleeding, intracranial bleeding, etc.);\n8. Patients who are unable to rely during the trial and\u002For follow-up stage and who are participating in other clinical studies at the same time.\n\n   * For patients who intend to use PD-1 monoclonal antibodies, if the patient has any of the following conditions, PD-1 monoclonal antibodies will not be used, and only the DEP regimen that does not contain PD-1 monoclonal antibodies will be used:\n\n     1. Those who are allergic to PD-1 monoclonal antibody components.\n     2. Abnormal thyroid function.\n     3. Those who have other severe immune reaction tendencies, including immune myocardial injury, immune hepatitis, immune pneumonia, etc.","70 Years",{"count":251,"type":21},20,[253],"PHASE4","This study is trying to evaluate the efficacy and safety of modified DEP regimens for the treatment of active hemophagocytic lymphohistiocytosis.",[26],"NOT_YET_RECRUITING","2024-08-01",{"date":259,"type":33},"2024-08-05",{"date":257,"type":21},{"date":262,"type":21},"2027-02-01",{"name":264,"class":40},"The First Affiliated Hospital of Soochow University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":51,"phases":275,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":41},"100553871","a-study-on-efficacy-and-safety-of-ink-cells-for-caebv-ebv-hlh-after-allo-hsct-100553871","NCT06491719","A Study on Efficacy and Safety of iNK Cells for CAEBV \u002FEBV-HLH After Allo-HSCT","A Study on Efficacy and Safety of iNK Cell Infusion in Patients With Chronic Active Epstein-Barr Virus Infection (CAEBV) and Epstein Barr Virus-induced Haemophagocytic Lymphohistiocytosis (EBV-HLH) After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n1. Patients with CAEBV or EBV-HLH who are eligible for allogeneic hematopoietic stem cell transplantation meet one of the following criteria:\n\n   ①EBV-DNA (PBMC or plasma) was still more than 103 before transplantation；②Positive for Cerebrospinal fluid EBV-DNA；\n\n   ③Abnormal phenotypic lymphocytes could still be detected in bone marrow immunotyping；\n\n   ④Measurable EBV-related lesions on imaging；\n2. ≤65 years，ECOG :0-2；\n3. Cardiac EF≥40%, creatinine clearance ≥50%; aminotransferase（ALT\u002FAST）\\\u003C200U\u002FL。；\n4. In patients with HLH, HLH efficacy ≥Partial Response after prior treatment is required；\n5. Estimated survival time is longer than three months；\n6. Agree to sign the Informed Consent Form。\n\nExclusion Criteria:\n\n1. Patients with evidence of grade II or more serious heart disease according to the New York Heart Association (NYHA) score (including Grade II) ; Clear diagnosis of cirrhosis；\n2. Active infections other than EBV that have not yet been controlled；\n3. Positive for hepatitis B virus or hepatitis C virus；\n4. Active massive hemorrhage of internal organs (including gastrointestinal hemorrhage, alveolar hemorrhage, intracranial hemorrhage, etc.)；\n5. Also participation in other interventional clinical studies within 4 weeks","65 Years",{"count":274,"type":21},15,[276],"NA","To evaluate the efficacy and safety of iNK cells infusion in patients with chronic active Epstein-Barr virus infection (CAEBV) and EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) after allogeneic hematopoietic stem cell transplantation (allo-HSCT)",[279,280,26],"CAEBV (Chronic Active Epstein-Barr Virus Infection) Syndrome","EBV","2024-07-09",{"date":283,"type":33},"2024-07-11",{"date":285,"type":21},"2024-07-15",{"date":287,"type":21},"2026-07-15",{"name":289,"class":40},"Beijing Friendship Hospital",{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":51,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":41},"100515182","efficacy-and-safety-of-carrimycin-tablets-in-hlh-patients-with-carbapenem-resistant-infections-100515182","NCT05988177","Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections","Clinical Study on the Efficacy and Safety of Carrimycin Tablets in Hemophagocytic Lymphohistiocytosis Patients With Carbapenem-resistant Infections","Inclusion Criteria:\n\n* Met HLH-2004 diagnostic criteria;\n* Active infection；\n* Empirical treatment with carbapenems did not respond after 72 hours；\n* Age \\>18 years old, no gender limitation;\n* Ability and willingness to adhere to the study visit schedule and all protocol requirements.\n\nExclusion Criteria:\n\n* Other antibiotics should be selected according to the results of drug sensitivity；\n* Systemic antibiotics other than carbapenems are used with 72 hours；\n* Inability to take oral medications due to disease of gastrointestinal tract；\n* Severe liver insufficiency;\n* Expected survival time \\\u003C 1 month;\n* Pregnant or breasting-feeding women;\n* Allergic to Carrimycin tablets;\n* Active hepatitis B or hepatitis C infection;\n* Patients with HIV infection;\n* Patients with other contraindications considered unsuitable for participation in this study.",{"count":251,"type":21},[276],"This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.",[301,26],"Carbapenem Resistant Bacterial Infection","2023-08-04",{"date":304,"type":33},"2023-08-14",{"date":306,"type":21},"2023-08-30",{"date":308,"type":21},"2026-12-30",{"name":289,"class":40}]